Health Care | Health Care Equipment & Services | Health Care Equipment & Supplies | Health Care Equipment
NASDAQ | Common Stock
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers.
The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.
Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma.
The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe.
The company was founded in 1988 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 11, 20 | -1.16 Increased by +99.88% | -1.63 Increased by +28.83% |
| Aug 13, 20 | -1.90 Increased by +96.75% | -1.69 Decreased by -12.43% |
| May 14, 20 | -108.07 Decreased by -43.88% | - |
| Mar 25, 20 | 186.19 Increased by +125.04% | - |
| Nov 14, 19 | -986.44 Decreased by -469.07% | - |
| Jul 14, 19 | -58.50 Increased by +98.85% | - |
| Jun 14, 19 | -75.11 Decreased by -100.98% | - |
| Mar 13, 19 | -743.73 Increased by +98.77% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 20 | 466.00 K Increased by +22.63% | -4.99 M Increased by +33.62% | Decreased by -1.07 K% Increased by +45.87% |
| Jun 30, 20 | 379.00 K Decreased by -8.01% | -4.28 M Increased by +28.26% | Decreased by -1.13 K% Increased by +22.01% |
| Mar 31, 20 | 294.00 K Increased by +8.89% | -7.86 M Increased by +0.41% | Decreased by -2.67 K% Increased by +8.54% |
| Dec 31, 19 | 518.00 K Decreased by -49.36% | 12.49 M Increased by +214.93% | Increased by +2.41 K% Increased by +326.98% |
| Sep 30, 19 | 380.00 K Decreased by -53.88% | -7.52 M Increased by +15.33% | Decreased by -1.98 K% Decreased by -83.61% |
| Jun 30, 19 | 412.00 K Decreased by -51.98% | -5.96 M Increased by +10.50% | Decreased by -1.45 K% Decreased by -86.39% |
| Mar 31, 19 | 270.00 K Decreased by -61.54% | -7.89 M Decreased by -209.82% | Decreased by -2.92 K% Decreased by -385.54% |
| Dec 31, 18 | 1.02 M Increased by +45.31% | -10.87 M Increased by +43.53% | Decreased by -1.06 K% Increased by +61.14% |